REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their proprietary informatics platform, today announced the hiring of Sharon Tetlow as chief financial officer.
“We are delighted to welcome Ms. Tetlow to the Pathwork team,” said Deborah Neff, chief executive officer of Pathwork. “Sharon’s considerable experience as CFO in both public and private companies will be invaluable as we execute our strategy to create and commercialize high value molecular diagnostics to help guide cancer treatment.”
“I am thrilled to join Pathwork’s outstanding management team during this exciting time in the company’s history,” said Ms. Tetlow. “Pathwork’s proprietary informatics platform has proven itself with the Pathwork® Tissue of Origin Test, and has enormous further potential. I look forward to contributing to the company’s next stage of growth.”
Ms. Tetlow has over a dozen years of experience as CFO in life sciences and a strong track record of strategic execution and capital raising. She was most recently senior vice president and CFO of Cell Genesys, a publicly traded biotechnology company which she was instrumental in selling to BioSante (BPAX). She served as a venture partner at Apax Partners, a private equity and venture firm, and previously served as senior vice president and chief financial officer of diaDexus, where she raised private capital to fund the development and successful launch of the company’s first product.
She also served as CFO of Reprogen and Terrapin, both private biotechnology companies. Prior to Terrapin, Ms. Tetlow worked in finance at Synergen, Genentech and Eli Lilly. Ms. Tetlow began her career in Washington D.C. where she worked in consulting at Lewin and Associates and then at the Brookings Institution. She holds a BA from the University of Delaware and an MBA from Stanford University.
About the Pathwork Tissue of Origin Test
The company’s Pathwork Tissue of Origin Test is the only FDA-cleared, Medicare-covered molecular diagnostic test for tissue of origin. It uses a tumor's own genomic information to help pathologists and oncologists in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history.
The Pathwork Tissue of Origin Test, available through the Pathwork Diagnostics Laboratory, measures gene expression levels of 2,000 genes and uses proprietary algorithms to compare the tumor’s gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90% of all solid tumors. The test provides objective genomic information to help the physician diagnose what type of cancer the patient has. Diagnosis allows oncologists to match therapy to the cancer.
The Pathwork Tissue of Origin Test has been extensively evaluated in multiple independent studies involving more than 1,100 patient specimens, including large validation studies published in the Journal of Clinical Oncology and the Journal of Molecular Diagnostics.
A retrospective study of 111 cases from 66 academic and community oncology practices illustrates the use of the test in management of cancer patients. Over two thirds of the cases reviewed showed cancer management changed after the Pathwork Tissue of Origin Test result was received. The majority of the oncologists identified the Tissue of Origin Test results as influencing the decision to make a change in therapy.
About Pathwork Diagnostics
Pathwork Diagnostics created its proprietary informatics platform to develop high-value, medically important diagnostics aimed at helping guide cancer care. Pathwork has commercialized its first product, the Pathwork Tissue of Origin Test, and is poised to further aid oncologists and pathologists through development of clinical products based on genomic analysis. Pathwork is privately held and based in Redwood City, CA. For more information call toll-free (877) 808-0006 or visit www.pathworkdx.com.